2022
580 Biodegradable bioadhesive nanoparticle delivery of chemotherapy for the treatment of cutaneous malignancies
Chang J, Suh H, Lewis J, Bosenberg M, Saltzman W, Girardi M. 580 Biodegradable bioadhesive nanoparticle delivery of chemotherapy for the treatment of cutaneous malignancies. Journal Of Investigative Dermatology 2022, 142: s99. DOI: 10.1016/j.jid.2022.05.589.Peer-Reviewed Original Research
2019
1019 Biodegradable bioadherent nanoparticle formulation for the local nonsurgical treatment of cutaneous malignancy
Hu J, Suh H, Lewis J, Lee A, Saltzman W, Girardi M. 1019 Biodegradable bioadherent nanoparticle formulation for the local nonsurgical treatment of cutaneous malignancy. Journal Of Investigative Dermatology 2019, 139: s176. DOI: 10.1016/j.jid.2019.03.1095.Peer-Reviewed Original Research
2018
441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies
Isufi I, Seropian S, Cooper D, Roberts K, Wilson L, Girardi M, Perreault S, Foss F. 441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies. Transplantation And Cellular Therapy 2018, 24: s307. DOI: 10.1016/j.bbmt.2017.12.353.Peer-Reviewed Original Research
2010
The contribution of Langerhans cells to cutaneous malignancy
Lewis J, Filler R, Smith DA, Golubets K, Girardi M. The contribution of Langerhans cells to cutaneous malignancy. Trends In Immunology 2010, 31: 460-466. PMID: 21071271, PMCID: PMC3753793, DOI: 10.1016/j.it.2010.10.001.Peer-Reviewed Original ResearchConceptsLangerhans cellsDendritic cellsRole of LCsIntraepidermal dendritic cellsAntigen-presenting cellsDC populationsCutaneous malignanciesImmunological organT cellsAdaptive immunitySkin cancerMalignant transformationEnvironmental exposuresUnique populationPotential roleCancerEpithelial tissuesCellsRecent studiesSkinMigratory changesMalignancyPathogenesisPopulationImmunityMore or Less: Copy Number Alterations in Mycosis Fungoides
Lin WM, Girardi M. More or Less: Copy Number Alterations in Mycosis Fungoides. Journal Of Investigative Dermatology 2010, 130: 926-928. PMID: 20231832, DOI: 10.1038/jid.2009.370.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesSkin-homing T cellsNon-Hodgkin lymphomaT-cell lymphomaCutaneous plaquesLymph nodesTumor involvementT cellsSkin diseasesLymphomaHeterogeneous groupGenetic alterationsCommon formGenomic DNA alterationsFungoidesNumber alterationsDNA alterationsAlterationsPrognosisMalignancyPathogenesisPlaquesDiseaseBlood
2007
Cutaneous two-stage chemical carcinogenesis.
Filler RB, Roberts SJ, Girardi M. Cutaneous two-stage chemical carcinogenesis. Cold Spring Harbor Protocols 2007, 2007: pdb.prot4837. PMID: 21357170, DOI: 10.1101/pdb.prot4837.Peer-Reviewed Original ResearchTwo-stage chemical carcinogenesisChemical carcinogenesisCutaneous malignanciesCutaneous tumorsCutaneous carcinogenesisBenign papillomasImmunological pathwaysPrecursor lesionsTopical administrationPro-inflammatory phorbol estersCancer developmentMouse skinTumor susceptibilityCarcinogenesisTumorsProgressionPhorbol esterLate eventSkinInductionMalignancyPapillomasLesionsMiceAdministration
2003
Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow
Girardi M, Knobler R, Edelson R. Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematology/Oncology Clinics Of North America 2003, 17: 1391-1403. PMID: 14710891, DOI: 10.1016/s0889-8588(03)00106-0.Peer-Reviewed Original ResearchConceptsLow side effect profileSide effect profilePotential novel strategyMechanism of actionImmunosuppressive medicationsExtracorporeal photochemotherapyEffect profileTransplant rejectionTreatment of cancerClinical recordsRole of ECPClinical studiesT cellsTreatment considerationsModern therapeuticsTreatmentNovel strategyGVHDMedicationsAutoimmunityCTCLMalignancyECPTherapyCancer
2001
Regulation of Cutaneous Malignancy by γδ T Cells
Girardi M, Oppenheim D, Steele C, Lewis J, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar R, Hayday A. Regulation of Cutaneous Malignancy by γδ T Cells. Science 2001, 294: 605-609. PMID: 11567106, DOI: 10.1126/science.1063916.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsCarcinogensCell LineCytotoxicity, ImmunologicDimerizationEpidermisEpithelial CellsHistocompatibility Antigens Class IHumansImmunologic SurveillanceLigandsMembrane ProteinsMiceMice, Inbred C57BLMinor Histocompatibility AntigensMolecular Sequence DataNK Cell Lectin-Like Receptor Subfamily KProtein ConformationProtein FoldingReceptors, Antigen, T-Cell, alpha-betaReceptors, Antigen, T-Cell, gamma-deltaReceptors, ImmunologicReceptors, Natural Killer CellRecombinant Fusion ProteinsReverse Transcriptase Polymerase Chain ReactionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT cellsGammadelta cellsLocal T cellsNatural killer cellsΓδ T cellsGammadelta T cellsCytolytic T cellsSkin carcinoma cellsNKG2D engagementMultiple regimensKiller cellsCutaneous malignanciesCutaneous carcinogenesisEpithelial malignanciesRAE-1Human MICAMalignancyCarcinoma cellsSkin cellsCellsNKG2DRegimensMiceEpitheliumCarcinogenesis
2000
Cutaneous T-cell lymphoma: pathogenesis and treatment.
Girardi M, Edelson RL. Cutaneous T-cell lymphoma: pathogenesis and treatment. Oncology 2000, 14: 1061-70; discussion 1070-4, 1076. PMID: 10929591.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaSkin immune systemImmune systemT cellsManagement of CTCLCutaneous T-cellMemory T cellsT helper cellsT-cell lymphomaSelective adhesion moleculeLymph nodesClinical spectrumPeripheral bloodCutaneous pathogensMajor subtypesPathogenesisAdhesion moleculesLymphomaDistinctive subsetTreatmentNormal functioningCellsBetter understandingImmunosurveillanceMalignancy